Presbia (LENSF) 10-K 30 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 30, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	1,591,096
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,121,857
Entity Public Float			$ 10,932,997

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 3,236	$ 7,333
Accounts receivable	8	3
Inventory	127	302
Prepaid expenses and other current assets	108	392
Total current assets	3,479	8,030
Property and equipment, net	477	727
Intangible assets, net	1,479	1,494
Other assets	127	126
Total assets	5,562	10,377
Current liabilities
Accounts payable	628	399
Due to related parties	23	18
Note payable, current portion	480	490
Other current liabilities	1,151	634
Total current liabilities	2,282	1,541
Note payable, net of current portion		369
Deferred rent	107	28
Due to related parties, net of current portion	12
Other liabilities, net of current portion	30
Total liabilities	2,431	1,938
Commitments and contingencies (note 12)
Shareholders' equity
Ordinary Shares $0.001 par value, 350,000,000 shares authorized; 13,420,927 and 13,335,477 shares issued and outstanding at December 31, 2017 and 2016, respectively	17	13
Deferred Ordinary Shares € 1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at December 31, 2017 and 2016	54	54
Preferred Shares $0.001 par value, 50,000,000 shares authorized; -0- shares issued and outstanding at December 31, 2017 and 2016
Additional paid-in capital	91,362	79,676
Accumulated deficit	(88,302)	(71,304)
Total shareholders' equity	3,131	8,439
Total liabilities and shareholders’ equity	$ 5,562	$ 10,377

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2017$ / sharesshares	Dec. 31, 2017€ / sharesshares	Dec. 31, 2016$ / sharesshares	Dec. 31, 2016€ / sharesshares
Statement Of Financial Position [Abstract]
Ordinary shares, par value | $ / shares	$ 0.001		$ 0.001
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000	350,000,000
Ordinary shares, shares issued	17,121,857	17,121,857	13,420,927	13,420,927
Ordinary shares, shares outstanding	17,121,857	17,121,857	13,420,927	13,420,927
Deferred ordinary shares, par value | (per share)	$ 1.35	€ 1	$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares issued	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares outstanding	39,994	39,994	39,994	39,994
Preferred shares, par value | $ / shares	$ 0.001		$ 0.001
Preferred shares, shares authorized	50,000,000	50,000,000	50,000,000	50,000,000
Preferred shares, shares issued	0	0	0	0
Preferred shares, shares outstanding	0	0	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Revenues	$ 14	$ 14
Cost of goods sold	97	279
Gross loss	(83)	(265)
Operating expenses:
Research and development	7,074	5,541
Sales and marketing	3,278	3,103
General and administrative	6,280	6,750
Total operating expenses	16,632	15,394
Operating loss	(16,715)	(15,659)
Interest expense, net	37	20
Other expense	1	2
Loss before income tax provision	(16,753)	(15,681)
Income tax provision	245	76
Net loss	(16,998)	(15,757)
Total comprehensive loss	$ (16,998)	$ (15,757)
Net loss per share - basic and diluted	$ (1.04)	$ (1.18)
Weighted average, shares outstanding - basic and diluted	16,298,505	13,337,560

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Ordinary Shares [Member]	Deferred Shares [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 22,025	$ 13	$ 54	$ 77,505	$ (55,547)
Balance, shares at Dec. 31, 2015		13,355,477	39,994
Stock-based compensation	2,171			2,171
Issuance of restricted stock, shares		65,450
Net loss	(15,757)				(15,757)
Balance at Dec. 31, 2016	8,439	$ 13	$ 54	79,676	(71,304)
Balance, shares at Dec. 31, 2016		13,420,927	39,994
Proceeds from issuance of ordinary shares from rights offering, net of costs	10,534	$ 4		10,530
Proceeds from issuance of ordinary shares from rights offering, net of costs, shares		3,611,764
Stock-based compensation	1,156			1,156
Issuance of restricted stock, shares		89,166
Net loss	(16,998)				(16,998)
Balance at Dec. 31, 2017	$ 3,131	$ 17	$ 54	$ 91,362	$ (88,302)
Balance, shares at Dec. 31, 2017		17,121,857	39,994

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities:
Net loss	$ (16,998)	$ (15,757)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	477	253
Inventory provisions	90	278
Loss on disposal of fixed assets	1	4
Stock-based compensation	1,168	2,171
Imputed interest expense	83	37
Changes in operating assets and liabilities:
Accounts receivable	(5)	113
Inventory	85	(149)
Prepaid expenses and other current assets	286	16
Other assets	(1)	(98)
Accounts payable and other current liabilities	528	(305)
Income taxes payable	231	8
Deferred rent	79	59
Due to related parties	5	(37)
Net cash used in operating activities	(13,971)	(13,407)
Cash flow from investing activities:
Purchase of intangible assets	(125)	(145)
Purchases of property and equipment	(73)	(140)
Net cash used in investing activities	(198)	(285)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares from rights offering, net of costs	10,534
Deferred offering costs		(167)
Proceeds from sale of equipment		1
Net cash (used in) provided by financing activities	10,024	(682)
Net decrease in cash	(4,145)	(14,374)
Effect of exchange rate on cash	48	(42)
Cash balance at beginning of period	7,333	21,749
Cash balance at end of period	3,236	7,333
Supplemental disclosure of cash flow information:
Cash paid for income taxes	19	50
Supplemental disclosures of non-cash investing and financing activities:
Capitalized intangible asset costs included in accounts payable	15	4
Deferred offering costs included in accounts payable and other current liabilities		91
Note Payable To Neoptics A.G. [Member]
Cash flow from financing activities:
Payment of note payable to Neoptics A.G.	$ (510)	$ (516)

Basis of Presentation and Descr

Basis of Presentation and Description of the Business	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Description of the Business	(1) Basis of Presentation and Description of the Business Presbia PLC (the “Company” or “Presbia PLC”), an Irish public limited company, was formed on February 6, 2014 through the issuance of 40,000 shares of €1.00 each for 40,000 Euro (approximately $54,000) for the purpose of consummating an initial public offering (“IPO”) of its ordinary shares. Presbia PLC’s ultimate controlling shareholder, Presbia Holdings (the “Parent”), was organized in the Cayman Islands in 2007 as an exempted company with limited liability. On October 21, 2013, the Parent completed a restructuring (the “2013 Restructuring”) which involved the formation on September 13, 2013 of an interim holding company, Presbia Ireland, Limited, and the contribution by the Parent of 100% of its direct and indirect ownership interests in its business, assets and subsidiaries to Presbia Ireland, Limited. On November 30, 2014, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by certain subsidiaries of Presbia Ireland, Limited at that time to equity (“2014 Debt Conversion”). In the 2014 Debt Conversion, approximately $23.5 million of outstanding intercompany debt owed to Presbia Holdings was converted to equity of Presbia Ireland, Limited. On January 14, 2015, Presbia Holdings converted all the remaining indebtedness owed to Presbia Holdings by a subsidiary of Presbia Ireland, Limited at that time to equity (the “2015 Debt Conversion”) in the amount of approximately $1.6 million. On January 14, 2015, the Parent contributed all the share capital in issue in Presbia Ireland, Limited to Presbia PLC (the “2015 Capital Contribution”) in exchange for 9,166,667 ordinary shares of US$0.01 each of Presbia PLC. The aggregate 9,166,667 ordinary shares of Presbia PLC have been reflected as issued and outstanding as of the earliest date of the periods presented for purposes of computation of basic and diluted net loss per share. On February 3, 2015, Presbia PLC completed its initial public offering (“IPO”) of 4,166,667 of its ordinary shares at a price to the public of $10.00 per ordinary share and commenced trading on The NASDAQ Global Market under the symbol LENS. The Parent acquired 500,000 ordinary shares from the public offering. The net proceeds from the IPO consisted of aggregate gross proceeds of approximately $41.7 million less underwriting discounts and commissions of approximately $2.9 million and other issuance costs of approximately $2.0 million resulting in net proceeds of approximately $36.8 million. On August 3, 2015, Presbia Holdings completed the distribution of its holdings of 9,666,667 ordinary shares of Presbia PLC to its ordinary shareholders for the purpose of dissolving Presbia Holdings on November 25, 2015 and ceasing to be the Parent of Presbia PLC. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC, Presbia Ireland, Limited, organized in Ireland, Presbia Investments organized in the Cayman Islands and Presbia USA, Inc., and OPL, LLC. Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. All amounts are shown in U.S. dollars. The Company, which began to be formed on June 29, 2007, has developed and is marketing a surgical solution to the age-related vision condition known as presbyopia. The Company’s primary objectives have been twofold: (1) achieve commercial success in those parts of the world where the Company’s surgical procedure has been approved by regulatory agencies and (2) successfully apply to the United States Food and Drug Administration (the “FDA”) for the authorization to market and manufacture the surgical procedure in the United States. Other than the FDA clinical trials that begun in 2014 and will continue to at least 2018, this procedure is currently not authorized by the FDA and may not be manufactured, sold, distributed or surgically performed on any individual in the United States. The Company’s principal revenue generating activity is the sale of the Company’s microlens to approved ophthalmologist physicians who, in turn, perform the surgical procedure on their patient base. Presbia is authorized to sell, market and perform this procedure in 40 countries through its wholly-owned Dutch subsidiary, Presbia Cooperatief U.A. Activities to-date have consisted primarily of research and development and expansion of its commercial activities in selected markets outside the United States. Going Concern Uncertainty At December 31, 2017, the Company has an accumulated deficit of $88.3 million and it expects to incur additional operating losses through 2018, and possibly further. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at December 31, 2017, will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report on Form 10-K. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company needs to raise additional capital to fund its operations. It may raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates. Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange loss was $59,000 for the year ended December 31, 2017, and aggregate foreign exchange gain was $1,000 for the year ended December 31, 2016. Reclassifications Certain prior year balances within the consolidated financial statements have been classified to conform to current year presentation. Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash. Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. The Company’s debt obligation approximates fair value as a result of imputed interest which approximates prevailing market rates. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values. Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2017 and 2016, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts. Inventory The Company accounts for inventory at the lower of market or cost. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete. Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss. Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment. Intangible Assets On August 2, 2016, Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement (the “Agreement”) with Neoptics AG (“Neoptics”) pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and the U.S. Dollar on August 2, 2016) payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The assets acquired include patents, pending patents, and other immaterial assets. Effective August 2, 2016, the Company became responsible for all expenses associated with such assets. Pursuant to the terms of the Agreement, the acquisition closed on August 2, 2016. The Company included a reclassification of $516,000 from cash flow from investing activities to cash flow from financing activities in its Consolidated Statements of Cash Flows for the year ended December 31, 2016. This reclassification is related to its payment of the first installment to Neoptics and conforms to current year presentation. Substantially all of the fair value of the gross assets acquired is concentrated in the acquired intellectual property rights or patents and not in the trademarks, documents or electronic data obtained from the Seller. The Company determined the intellectual property right or patents were akin to inputs within the scope of ASC 805 “Business Combinations” and that no substantive processes were acquired in the assets acquisition. Therefore, the Company applied the asset acquisition accounting guidance in ASC 805-50-30 “ Initial Measurement of Acquisition of Assets Rather than a Business The Company paid $0.6 million in cash in exchange for these patents and patent applications in the year ended December 31, 2017. The useful life of the patents was determined to be 12 years and 4 months and will be amortized through November 25, 2028. The Company recorded amortization expense of approximately $140,000 with net carrying amount of approximately $1,477,000 as of December 31, 2017. At December 31, 2017, a note payable of $480,000 is recorded on the consolidated Balance Sheet in connection with the final payment due by December 31, 2018. For fiscal years 2018 to 2022, approximately $135,000 will be recorded annually as amortization expense for the Neoptics assets. Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2017 and 2016, the Company capitalized $0 associated with website development. Amortization expense of $15,000 was recorded in each of the years ended December 31, 2017 and 2016. Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the years ended December 31, 2017 and 2016. Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. In the years ended December 31, 2017 and 2016 there were four and three customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2017, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. The Company recognized revenues of $14,000 from foreign ophthalmic clinics during the years ended December 31, 2017 and 2016. Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense. Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Additionally, the fair value of restricted stock units is determined using a Monte Carlo Simulation, or “MCS”, methodology, which considers the separate probabilities that of the price thresholds or market conditions will be achieved under the Restricted Stock Units Plan guidelines. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company. Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for a capital raise are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the capital raise is concluded as a reduction of the proceeds of the capital raise as part of additional paid in capital. On December 5, 2016, the Company filed with the SEC a Form S-1 Registration Statement under the Securities Act of 1933 for the purpose of distributing to holders of the Company’s ordinary shares, non-transferable and non-tradeable subscription rights to purchase ordinary shares (“rights offering”). During the years ended December 31, 2017 and 2016, the Company incurred approximately $0.3 million and $0.2 million related to its rights offering, respectively, which was completed on March 8, 2017. Upon completion of the rights offering, the Company netted approximately $0.3 million in offering costs against the gross proceeds in shareholders’ equity as of December 31, 2017. Income Taxes As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized. Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the consolidated statements of operations and comprehensive loss in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $395,000, and $198,000 as part of sales and marketing expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2017 and 2016, respectively. Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s Recently Adopted Accounting Standards In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes ASU 2015-17 became effective January 1, 2017 and did not have a material impact on our consolidated financial statements. In March 2016, the Financial Accounting Standards Board issued ASU 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ASU 2016-09 became effective January 1, 2017 and did not have a material impact on our consolidated financial statements. Future Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-2 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In October 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, In February 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory	(3) Inventory The Company maintains a serial number tracking system that measures shelf life such that no lens that has aged beyond four years shall be delivered to a customer. During the years ended December 31, 2017 and 2016, inventory write-downs reflecting excess quantities on hand were recognized in the amount of $90,000 and $278,000, respectively, based on the age of the lens inventory, inserters, accessories and the refractive mix of the inventory. Finished goods inventory consists of the following (in thousands): December 31, 2017 2016 Lenses $ 55 $ 175 Accessories 72 127 Inventory $ 127 $ 302

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment, net	(4) Property and Equipment, net Property and equipment, net consist of the following (in thousands): December 31, 2017 2016 Office equipment and computers $ 79 $ 78 Leasehold improvements 214 168 Production equipment and facilities 802 788 Software 62 62 Furniture and vehicles 237 227 1,394 1,323 Less: accumulated depreciation (917 ) (596 ) Property and equipment, net $ 477 $ 727 Depreciation and amortization expense related to property and equipment for the years ended December 31, 2017 and 2016 was $322,000 and $186,000, respectively and classified as part of operating expenses in the Consolidated Statements of Operations and Comprehensive Loss for all periods. In connection with the closure of an office facility in December 2017, approximately $67,000 of unrecognized depreciation for furniture and leasehold improvements and $52,000 of engineering tools, molds and fixtures were recorded in the Consolidated Statements of Operations and Comprehensive Loss for the period ended December 31, 2017 (see Note 14).

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Note Payable	(5) Note Payable Note payable is summarized as follows (in thousands): December 31, 2017 2016 Noninterest bearing note payable to Neoptics A.G. $ 518 $ 981 Less present value discount (38 ) (122 ) Note payable, net 480 859 Less current portion 480 490 Note payable, long term $ — $ 369 Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement with Neoptics AG pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and US Dollar on August 2, 2016), bearing no interest and payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The Company recorded the intangible asset and a loan discount using a rate of 9%. The remaining liability is recorded in the Company’s balance sheet, net of unamortized discount of $38,000 at December 31, 2017. The discount on the note payable is being amortized to imputed interest expense over the life of the note.

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2017
Other Liabilities Current [Abstract]
Other Current Liabilities	(6) Other Current Liabilities Other current liabilities consist of the following as of the dates set forth below (in thousands): December 31, 2017 2016 Accrued payroll and severance related $ 352 392 Accrued professional fees 109 71 Accrued clinical expense 125 — Accrued deferred rent expense 236 52 Accrued other expense 46 67 Income tax payable 283 52 $ 1,151 $ 634 Other current liabilities for the year ended December 31, 2016 includes a reclassification of $52,000 related to the current portion of deferred rent, to conform to the current year presentation.

Loss per Share

Loss per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Loss per Share	(7) Loss per Share Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period, less unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2017 2016 Net Loss $ (16,998 ) $ (15,757 ) Net income allocated to participating securities — — Net loss allocated to common shareholders $ (16,998 ) $ (15,757 ) Weighted average shares outstanding - basic and diluted 16,298,505 13,337,560 Basic and diluted net loss per share $ (1.04 ) $ (1.18 ) Antidilutive securities, which consist of options and restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of 1,037,964 and 1,082,916 weighted average shares for the fiscal years ended December 31, 2017 and 2016, respectively.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Shareholders' Equity	(8) Shareholders’ Equity Ordinary Shares As of December 31, 2017, our authorized share capital includes $400,000 and €40,000 divided into 350,000,000 ordinary shares of $0.001 each, which we refer to as the ordinary shares. The rights and preferences of the ordinary shares are as follows: (i) subject to the right of the Company to set record dates for the purposes of determining the identity of shareholders entitled to notice of and/or to vote at a general meeting, the right to attend and speak at any general meeting of the Company and to exercise one vote per ordinary share held at any general meeting of the Company; (ii) the right to participate pro rata in all dividends declared by the Company; and (iii) the right, in the event of the Company’s winding up, to participate pro rata in the total assets of the Company. The rights attaching to the ordinary shares may be subject to the terms of issue of any series or class of preferred shares allotted by the Company’s board of directors from time to time in accordance with our articles of association. Deferred Ordinary Shares Capital related to Presbia PLC at December 31, 2014 consisted of ordinary shares of €1.00 each (“Euro Ordinary Shares”) of $54,000, €1.00 par value, 40,000 authorized and issued with effective date of formation of February 6, 2014 (paid-in on January 10, 2014 with $1.35: €1.00), being $54,000 in aggregate. On January 14, 2015 the Company amended its memorandum and articles of association, resulting in the re-designation of the 40,000 Euro Ordinary Shares as deferred ordinary shares (“Deferred Ordinary Shares”). In August 2015, the Company cancelled 6 Deferred Ordinary Shares pursuant to the distribution of assets held by Presbia Holdings to its ordinary shareholders and 39,994 Deferred Ordinary Shares held by Presbia Holdings were transferred to Richard Ressler. Our articles of association provide that the holders of Deferred Ordinary Shares shall not be entitled to receive notice of, nor attend, speak or vote at, any general meeting of the Company and the holders of Deferred Ordinary Shares shall not be entitled to receive any dividend or distribution declared, made or paid or any return of capital or to any further or other right of participation in the assets of the Company. On a winding up of, or other return of capital (other than on a redemption of any class of shares in the capital of the Company) by the Company, the holders of Deferred Ordinary Shares are entitled to participate in such return of capital or winding up, such entitlement to be limited to the repayment of the amount paid up or credited as paid up on such Deferred Ordinary Shares, which shall be paid only after the holders of ordinary shares have received payment in respect of such amount as is paid up or credited as paid up on those ordinary shares held by them at that time, plus the payment in cash of $5,000,000 on each such ordinary share. The rights attaching to the Deferred Ordinary Shares may be subject to the terms of issue of any series or class of preferred shares allotted by the Company’s board of directors from time to time in accordance with our articles of association. Preferred Shares Our authorized share capital also includes 50,000,000 preferred shares of $0.001 each, which we refer to as preferred shares. As of December 31, 2017, no preferred shares have been issued. Our articles of association authorize our Board, without shareholder approval, to determine the terms of the preferred shares that may be issued by us. Our Board is authorized, without obtaining any shareholder vote or consent, unless expressly provided by the terms of that class or series of class of shares, to provide from time to time for the issuance of ordinary shares or other classes or series of shares and to establish the characteristics of each such other class or series, including the number of shares, designations, relative voting rights, dividend rights, liquidation and other rights, redemption, repurchase or exchange rights and any other preferences and relative, participating, optional or other rights and limitations not inconsistent with applicable law. Shares Issuable Pursuant to Services Agreement with OCV Management, LLC On December 14, 2017, the Company concluded a services agreement with OCV Management, LLC for the purpose of providing management services for the Company for the period commencing December 14, 2017 until terminated upon thirty (30) days’ prior written notice by either of the parties. OCV Management, LLC will receive an annual fee of $250,000, payable annually in arrears. The obligation will be settled in the form of ordinary shares issued by the Company in a private offering. For 2018, the number of shares to be issued will be determined by dividing $250,000 by the closing price on January 2, 2018 and the shares will be issued on January 2, 2019. The Company recorded a non-current liability and a corresponding stock-based compensation expense of $12,000 as of December 31, 2017 in relation to services provided in 2017.

Equity Based Awards

Equity Based Awards	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Based Awards	(9) Equity Based Awards Presbia Incentive Plan On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted stock units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 2,200,000 ordinary shares were authorized for issuance under the Presbia Incentive Plan of which approximately 435,141 were available on December 31, 2017 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the Presbia Incentive Plan awards, and generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2017 and 2016. Year Ended December 31, 2017 2016 Research and development $ 251 $ 259 General and administrative 951 1,549 Sales and marketing (34 ) 363 $ 1,168 $ 2,171 Following the December 2017 reorganization in which 15 employees were terminated, approximately $970,000 was recorded as a reduction to share-based compensation expense in connection with the extension of vesting and exercise periods related to equity awards for these employees (see Note 14). Options The following table sets forth the Company’s option activity for the year ended December 31, 2017: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2017 1,050,000 $ 9.77 — Granted — $ — — Exercised — $ — — Forfeited/cancelled/expired (200,900 ) $ 9.74 — Balance, December 31, 2017 849,100 $ 9.77 — Vested, December 31, 2017 590,800 $ 9.80 — Not Vested, December 31, 2017 258,300 $ 9.72 — Exercisable, December 31, 2017 590,800 $ 9.80 — Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of granted stock options with the following assumptions in addition to the closing price of the Company’s ordinary shares on the date of the grant: (i) the Company estimates the expected term of the option utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of a "plain-vanilla" option as defined by the Securities Exchange Commission (ii) due to its limited stock price volatility history, the Company uses a peer group average as permitted under ASC 718 consistent with the expected term of the stock option at the time of the grant and (iii) applies a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the option at the time of the grant. The simplified method calculates the expected term as the average of the weighted average vesting period and contractual terms of the award. For those options granted to employees, stock-based compensation expense is based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. A 3% forfeiture rate assumption was applied, which reduced the amount of expense recognized each period anticipating that a portion of all options granted would, more likely than not, be cancelled prior to the dates of its vesting periods. The forfeiture rate is subject to review and may be adjusted based upon experience. The Company did not issue employee options during the years ended December 31, 2017 and 2016. Non-Employee Options During the years ended December 31, 2017 and 2016, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Year Ended December 31, 2017 2016 Stock price per share $1.31 - $2.83 $2.50 - $3.49 Expected term 7.5 - 8.3 Yrs. 8.2 - 9.3 Yrs. Volatility 69.3% - 85.8% 66.1% - 92.6% Dividends — — Risk-free rate 2.2% - 2.4% 1.4% - 2.5% Because the performance criteria of these grants is based solely upon a requisite service period, but are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service period subject to a forfeiture rate of 3%. Restricted Shares Consistent with the Company’s director compensation policy, during the years ended December 31, 2017 and 2016, the Company’s board of directors approved the grant of 89,166 and 65,450 restricted ordinary shares of the Company, with a grant date weighted average fair value of $3.58 and $3.50, and one-year and three-year vesting periods, respectively. The following table sets forth the Company’s restricted share activity for the year ended December 31, 2017: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2016 81,682 $ 3.50 Granted 89,166 $ 3.58 Vested (36,481 ) $ 2.96 Forfeited/cancelled — — Unvested, December 31, 2017 134,367 $ 3.78 Restricted Stock Units During the year ended December 31, 2017, the Board of Directors approved the award of 97,500 restricted stock units (“RSU” or “RSU’s” or “RSU Plan”), respectively, to officers and employees in accordance with the guidelines provided by the Presbia Incentive Plan, which includes a provision that the recipient must be employed as a condition of vesting. The Presbia RSU Plan authorizes the issuance of 20% of each recipient’s total RSU award for the first occurrence that the closing price of the Company’s ordinary shares exceed, for a period of 20 consecutive business days, price thresholds of $10.00, $15.00, $20.00, $25.00 and $30.00, respectively. The RSU Plan also provides for a one-year “wait” or service period prior to any vesting permitted under the plan. The RSU Plan has a seven-year expiration period following the date of the grant. Fair value of the RSU’s awarded was determined using a MCS methodology, which considers the separate probabilities that each of the price thresholds or market conditions will be achieved under the RSU Plan guidelines. Each probability is weighted by its respective price threshold, or its intrinsic value, which provides the basis for an aggregate fair value. The Company used the following key inputs in determining the fair value using the MCS model: (i) the volatility of the entity’s common stock and (ii) the closing price of the entity’s stock as of the measurement date of the RSU award. In accordance with GAAP, the Company recognizes as stock-based compensation expense, using a straight-line attribution method, the aggregate fair value over future periods based upon the respective derived service periods and fair values for each of the price thresholds as provided by the MCS model. A 3% forfeiture rate was applied to account for future cancellations and forfeitures. During the years ended December 31, 2017 and 2016 approximately $302,000 and $467,000, respectively, was recorded as stock-based compensation related to the RSU Plan. During the year ended December 31, 2017, 60,000 restricted stock unit were granted to new employees and 37,500 restricted stock units were granted to existing employees. The following table sets forth the Company’s RSU activity for the year ended December 31, 2017: Unvested Number of Weighted Average Fair Shares Value per Share Balance, December 31, 2016 719,000 $ 3.10 Granted 97,500 $ 1.92 Vested — $ — Forfeited/cancelled (77,500 ) $ 2.90 Unvested, December 31, 2017 739,000 $ 2.09 As of December 31, 2017, 739,000 RSU’s were outstanding with none vested. Unrecognized Share-based Compensation As of December 31, 2017 and 2016, there were $0.5 million and $3.4 million, respectively, of unrecognized compensation expense related to employee and non-employee options of the Company, which collectively is expected to be recognized by the Company over the weighted average vesting period of 1.5 and 2.0 years, respectively. Unrecognized compensation expense for the same periods related to restricted shares was $0.2 million and $0.3 million, respectively, and is expected to be recognized over the weighted average vesting periods of 1.6 and 2.6 years, respectively. As of December 31, 2017, there was approximately $7.3 million of unrecognized compensation expense with respect to the RSU’s over a weighted average remaining derived service period of 2.0 years.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	(10) Related Party Transactions The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2017 2016 Payable to related parties-current: Management services provided by related parties $ 35 $ 18 Less current portion $ 23 $ 18 Management services provided by related parties, long term $ 12 $ — Since 2011, Orchard Capital Corporation (“Orchard”), which is wholly-owned by Mr. Ressler, has provided financial analysis and bookkeeping, accounting, legal, compliance and directorial services to the Company pursuant to a Services Agreement. During the years ended December 31, 2017, and 2016, the Company recognized general and administrative expense of $14,000 and $14,000, respectively, for services invoiced by Orchard. As of December 31, 2017 and 2016, amounts due to Orchard for management and accounting services amounted to $3,000 and $4,000, respectively. Commencing with the second quarter of 2013, the Company has received human resources management services, payroll services, IT support and risk management services from CIM Group, an entity in which Mr. Ressler has a controlling interest. The Company has incurred charges of $37,000 and $73,000 payable to CIM Group for such services for the years ended December 31, 2017 and 2016, respectively. As of December 31, 2017 and 2016, amounts due to CIM Group for human resources, payroll, information technology and legal services amounted to $19,000 and $14,000, respectively. On December 14, 2017, the Company concluded a services agreement with OCV Management, LLC, a related party co-founded by Mr. Ressler and Mark Yung, for the purpose of providing management services for the Company for the period commencing December 14, 2017 until terminated upon thirty (30) days’ prior written notice by either of the parties. OCV Management, LLC will receive an annual fee of $250,000, payable annually in arrears. The obligation will be settled in the form of ordinary shares issued by the Company in a private offering. For 2018, the number of shares to be issued will be determined by dividing $250,000 by the closing price on January 2, 2018 and the shares will be issued on January 2, 2019. The Company recorded a non-current liability of $12,000 as of December 31, 2017 in relation to services provided in 2017 (see Note 15).

Operating Segments and Geograph

Operating Segments and Geographic Information	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Operating Segments and Geographic Information	(11) Operating Segments and Geographic Information The Company operates in one operating segment, the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. Revenue originating in the United States is limited to intercompany transactions that do not result in any revenue generating activities to any individual or physician in the United States, and these amounts are eliminated upon consolidation. The operating losses in the United States result primarily from research and development and general and administrative costs while the operating losses in the foreign operations result primarily from sales and marketing costs and an allocation of general and administrative costs to foreign operations. Revenues from external customers to individual countries are allocated based on the location of the customer. For the periods presented, there was no more than one customer in each individual country. The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2017 2016 Australia $ 5 $ — New Zealand 1 — Canada — 1 Ireland — 14 Italy 3 — The Netherlands — (1 ) Germany 5 — Total $ 14 $ 14 Year Ended December 31, Long-lived Assets 2017 2016 U.S. 453 697 Foreign 24 30 Total $ 477 $ 727 In the years ended December 31, 2017 and 2016 there were four and three customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2017, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. With respect to suppliers for the microlens, the Company has a five-year supplier agreement that expired in January 2017 with a lens manufacturer in Israel from which the Company received 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that we believe can be scaled to meet excessive lens demand or a disruption of supply sourced from outside the United States.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(12) Commitments and Contingencies Facility Leases In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that was renewed on June 1, 2016 and provided for an extension of five consecutive years starting from the original lease expiration date of May 31, 2017 through May 31, 2022. The Company maintains a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013, and, in February 2018, it terminated a 30-month lease in Amsterdam, the Netherlands, that commenced on January 1, 2016. This termination was based on a mutual agreement with the landlord. The Company also maintains a four-year lease for office space in Irvine, California, that commenced on August 1, 2016 and will expire in September 2020. Aggregate rent expense for the years ended December 31, 2017 and 2016 was $867,000 and $388,000, respectively. The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2018 $ 580 2019 569 2020 494 2021 283 2022 120 Thereafter — Total $ 2,046 Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial statements.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2017 2016 Current provision: Federal $ — $ — State 2 4 Foreign 243 72 Total current $ 245 $ 76 Deferred provision Federal (3,335 ) (255 ) State — — Foreign 1,065 (1,228 ) Total deferred (2,270 ) (1,483 ) Valuation allowance 2,270 1,483 Total deferred — — Total income tax provision $ 245 $ 76 A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2017 2016 Expected income tax benefit at federal statutory rate 35 % 35 % State tax provision, net of federal benefit (0 %) 0 % Foreign rate differential (15 %) (25 %) Nondeductible expenses (0 %) 0 % Foreign Tax (1 %) 0 % Change in valuation allowance (4 %) (10 %) Effect of Change in Tax Rate (9 %) 0 % Other (7 %) 0 % Income tax provision (1.4 %) (0.0 %) The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 5,019 $ 4,444 Accrued expenses 31 195 Stock based compensation 0 (11 ) Deferred tax assets 5,050 4,628 Valuation allowance (5,033 ) (4,559 ) Net deferred tax assets 17 69 Deferred tax liabilities: Depreciation (17 ) (69 ) Total deferred tax liabilities (17 ) (69 ) Net deferred tax asset $ — $ — The valuation allowance has been established to offset the Company’s net deferred tax assets, as realization of such assets is not considered to be more likely than not due to the Company’s history of losses and uncertainties regarding the Company’s ability to generate future taxable income sufficient to realize the benefit of these deferred tax assets. The Company has U.S. Federal net operating loss (“NOL”) carryforwards of approximately $11.1 million and $2.0 million for December 31, 2017 and 2016 respectively, subject to potential limitations pursuant to Internal Revenue Code section 382 as discussed below. The federal NOL carryforwards will begin to expire in 2033, unless previously utilized. The Company has NOL carryforwards in Ireland of $21.5 million and $21.2 million for December 31, 2017 and 2016, respectively. Under Irish rules, only such losses that occur within a three year period prior to commencing trading can be utilized to offset future trading taxable income. Pursuant to Sections 382 of the Internal Revenue Code (the “Code”), annual use of the Company’s NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three year period. An ownership change may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income and tax. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain shareholders. As of December 31, 2017, the Company has provided a liability of $199,000 for unrecognized tax benefits relating to a foreign income tax matter. This amount is expected to reduce our effective income tax rate if recognized in future reporting periods. The Company does not anticipate a significant increase in the unrecognized tax benefits over the next 12 months. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of December 31, 2017 and December 31, 2016, the Company has $39,000 and $0, respectively, of tax related accrued interest and penalties on its balance sheet or on its statement of operations. A reconciliation of gross unrecognized tax benefits is as follows: Year Ended December 31, 2017 2016 Balance at the beginning of the year — — Increases related to current year tax positions 199,000 — Balance at the end of the year $ 199,000 $ — Due to net operating loss carryovers, the U.S. federal and state returns are open to examination by the Internal Revenue Service and state jurisdictions for years 2014 through 2017. The foreign income tax returns are open to examination for the years 2013 through 2017. On December 22, 2017, the President signed the Tax Cuts and Jobs Act (the 2017 Act) into law. The Act will have pervasive financial reporting implications for all companies with US operations, including reduction of the U.S. federal corporate tax rate from 35 percent to 21 percent. We reviewed and incorporated the new tax bill implications through 2017 financial statements. We remeasured the deferred taxes at new corporation rate of 21%, which reduced the net deferred tax assets, before valuation allowance, by $1,567,000. Due to full valuation allowance, the change in deferred taxes was fully offset by the change in valuation allowance. The 2017 Act has no significant impact on the 2017 financial statements. On December 22, 2017, Staff Accounting Bulletin No. 118, or SAB 118, was issued to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Act. During the measurement period, impacts of the law are expected to be recorded at the time a reasonable estimate for all or a portion of the effects can be made, and provisional amounts can be recognized and adjusted as information becomes available, prepared, or analyzed. Any subsequent adjustment to these amounts will be recorded to current tax expense in 2018 when the analysis is complete.

Fourth Quarter 2017 Adjustments

Fourth Quarter 2017 Adjustments	12 Months Ended
	Dec. 31, 2017
Restructuring And Related Activities [Abstract]
Fourth Quarter 2017 Adjustments	(14) Fourth Quarter 2017 Adjustments In December 2017, the Company announced a reorganization which resulted in a reduction of 15 employees, or 38.5% of total headcount, which affected payroll, benefits, severance and incentive pay expenses; reduced need for office space which resulted in vacant office space and termination costs; and adjustments to stock-based compensation expense related to modification of equity awards for terminated employees. In addition, the Company is recognizing a tax reserve of $238,000 for unpaid withholding taxes due to Irish tax authorities. The total amount of fourth quarter adjustments is a reduction in operating expense of $1,078,000 and an increase of tax provision expense of $238,000. • Compensation Related - ($465,000) In December 2017, 15 employees were terminated as the Company reprioritized its efforts towards achieving FDA clinical trials approval of its Microlens by the fourth quarter of 2018. Post-employment costs were approximately $332,000 consisting of severance costs to be paid out primarily over a six-month period ending June 2018 and a reversal of $797,000 in accrued incentive compensation costs for amounts that were accrued in 2017 but are not payable as of December 31, 2017. • Facilities Related - $357,000 Also, in December 2017, the Company vacated one of its Irvine, California facilities and consolidated its operations into another facility also located in Irvine. As of December 31, 2017, the remaining lease term of the vacated facility, of approximately 8,500 square feet, was 33 months through September 30, 2020. The Company recorded a current liability of $222,000 representing the fair value of the remaining lease obligation as part of the short-term portion of deferred rent on the Consolidated Balance Sheet as of December 31, 2017 (see note 6). The determination of the fair value was inclusive of reasonable prospective sublease assumptions, which may, or may not, materialize during the remaining term of the lease. These assumptions are reviewed and updated quarterly over the remaining term of the lease with possible adjustments to the accrual and corresponding increases or decreases to rent expense. In addition, the Company recorded write-downs of leasehold expenses, furniture and fixtures of an aggregate of $89,000 and accrued expense of $8,000 for unneeded telecom facilities. The Company also wrote down to net realizable value certain engineering tools, molds and fixtures related to discontinued engineering programs in the amount $52,000. • Stock-Based Compensation Related – ($970,000) Equity awards granted by the Company do not include provisions to extend the terms and conditions related to vesting or exercising an award beyond the date of termination of the optionee (or holder), with the exception of stock option grants that contain a provision that allows the holder to exercise vested options (vesting must have occurred on or prior to termination date) for a period of 90 days following termination. On the date of reorganization, the Company extended the terms and conditions for all equity grants for all terminated employees providing at least a one-year extension past the termination date for all vested stock options (Type I modification as prescribed by ASC 718), and, in certain cases, the acceleration of unvested options or restricted share awards (Type III modification as prescribed by ASC 718). For those terminated employees with RSU grants based on a market condition, the Company granted a one-year extension to vest according to the same market conditions as defined in the original grants. Generally, when a modification of an award occurs, the prior periods’ expense recognition associated with all unvested awards is reversed in the period of the modification on the basis that the old award is being exchanged for a new award. This resulted in a reduction of stock-based compensation expense of $1,350,000. The Company then compared the relative fair values of the old award with the terms and conditions of the modified award immediately before and after the date of modification and recorded the increase in fair value as stock-based compensation expense in the amount of $380,000, also in the same period of the date of modifications, resulting in a net reduction of stock-based compensation expense of $970,000. • Irish Taxes - $238,000 Under Irish law non-executive Directors of Irish companies, regardless of the tax residency of such Directors, are subject to Irish income tax related to meetings held in Ireland. The Company is also jointly liable for the Irish taxes. As of December 31, 2017, the Company has not paid or arranged to be paid approximately $238,000 in withholding of income taxes required under Irish law including potential penalties and interest costs associated with the remuneration of certain board of director members with tax residencies outside of Ireland for the fiscal years 2015 to 2017. The estimated amount due for 2017 is $70,000, which the Company intends to recover from directors. The Company is working with directs to recover amounts related to years prior to 2017. As of December 31, 2017, the Company recognized a reserve of $238,000 under FIN 48 , Accounting for Uncertainty of Income Taxes.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	(15) Subsequent Events On December 14, 2017, in connection with the December 2017 reorganization, the Company concluded a management services agreement with OCV Management, LLC, a related party (see Note 10), in which the consideration to be provided to OCV for its services would be in ordinary shares equivalent in value to an annual rate of $250,000 per year and the number of ordinary shares to be determined by the closing price of the Company’s ordinary shares as of January 2, 2018. The closing price on January 2, 2018 was $3.29 indicating that the number of ordinary shares required to settle the annual obligation in January 2019 is 75,988.

Basis of Presentation and Des22

Basis of Presentation and Description of the Business (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Going Concern Uncertainty	Going Concern Uncertainty At December 31, 2017, the Company has an accumulated deficit of $88.3 million and it expects to incur additional operating losses through 2018, and possibly further. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at December 31, 2017, will not be sufficient to meet its anticipated cash requirements during the twelve-month period subsequent to the issuance of the financial statements included in this Annual Report on Form 10-K. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date this Annual Report on Form 10-K is filed with the U.S. Securities and Exchange Commission (SEC). The Company’s current commercialization strategy is targeted to countries where the Company can establish the market for its technology. This commercialization strategy will undergo continual prioritization and in the future the Company may adjust its commercialization efforts to preserve its existing cash or realize better results than anticipated which could have a positive impact on cash. The Company’s U.S. pivotal clinical trial and planned FDA approval is its highest priority. The Company needs to raise additional capital to fund its operations. It may raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. Additional funds may not be available when the Company needs them on terms that are acceptable to the Company, or at all. If adequate funds are not available on acceptable terms, the Company may be required to delay, reduce the scope of, or curtail, its operations. To the extent that the Company raises additional funds by issuing equity securities, its shareholders will experience dilution, and debt financing, if available, may involve restrictive covenants.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires that management makes estimates and assumptions that are included in the consolidated financial statements and accompanying notes. The actual results may differ from those estimates.
Segment Information	Segment Information In accordance with Accounting Standard Codification (“ASC”) 280-10-50, Segment Reporting
Foreign Currency	Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange loss was $59,000 for the year ended December 31, 2017, and aggregate foreign exchange gain was $1,000 for the year ended December 31, 2016.
Reclassifications	Reclassifications Certain prior year balances within the consolidated financial statements have been classified to conform to current year presentation.
Concentrations of Credit Risks	Concentrations of Credit Risk Cash is generally deposited in demand deposit accounts that, from time to time, may exceed insurable limits. The Company has not experienced any losses from its deposits of cash.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying values of certain of the Company’s financial instruments, such as prepaid expenses, accounts payable and accrued expenses, approximate fair value due to their short maturities. The Company’s debt obligation approximates fair value as a result of imputed interest which approximates prevailing market rates. Amounts payable to related parties, including the payable due to the Parent, which has no fixed maturity or expiration date, do not have readily determinable fair values.
Cash	Cash The Company considers highly liquid investments with original maturities less than 90 days to be cash equivalents. As of December 31, 2017 and 2016, the Company had no such short-term investment instruments and maintained its cash in bank demand deposit accounts.
Inventory	Inventory The Company accounts for inventory at the lower of market or cost. Inventory is stated at weighted average cost, which is determined by applying the current average cost to the ending inventory. Inventory consists of lenses and lens inserters and other accessories used by physicians in the surgical process associated with the lenses. The Company maintains serialized records of all lenses, including the five-year expiration date of each lens, after which the lens cannot be sold. The Company considers the expiration dates of lenses, in addition to comparing the carrying amount of inventory to expected demand, and will write-down inventory for amounts determined to be excess or obsolete.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three to ten years. Leasehold improvements are amortized over the lesser of the useful life of the asset or the remaining term of the lease. Repairs and maintenance of property and equipment are expensed as incurred. Upon retirement or sale, the original cost and accumulated depreciation are removed and any gain or loss is recognized in the consolidated statements of operations and comprehensive loss.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews the recoverability of long-lived and finite-lived intangible assets when circumstances indicate that the carrying amount of assets might not be recoverable. This evaluation is based on various analyses, including undiscounted cash flow projections. In the event undiscounted cash flow projections indicate impairment, the Company would record an impairment based on the fair value of the assets at the date of the impairment.
Intangible Assets	Intangible Assets On August 2, 2016, Presbia Ireland, Limited, a wholly-owned subsidiary of the Company, entered into an asset purchase agreement (the “Agreement”) with Neoptics AG (“Neoptics”) pursuant to which the Company acquired certain assets from Neoptics for an aggregate purchase price of 1.5 million Swiss Francs (approximately $1.5 million based on the exchange rate between the Swiss Franc and the U.S. Dollar on August 2, 2016) payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018. The assets acquired include patents, pending patents, and other immaterial assets. Effective August 2, 2016, the Company became responsible for all expenses associated with such assets. Pursuant to the terms of the Agreement, the acquisition closed on August 2, 2016. The Company included a reclassification of $516,000 from cash flow from investing activities to cash flow from financing activities in its Consolidated Statements of Cash Flows for the year ended December 31, 2016. This reclassification is related to its payment of the first installment to Neoptics and conforms to current year presentation. Substantially all of the fair value of the gross assets acquired is concentrated in the acquired intellectual property rights or patents and not in the trademarks, documents or electronic data obtained from the Seller. The Company determined the intellectual property right or patents were akin to inputs within the scope of ASC 805 “Business Combinations” and that no substantive processes were acquired in the assets acquisition. Therefore, the Company applied the asset acquisition accounting guidance in ASC 805-50-30 “ Initial Measurement of Acquisition of Assets Rather than a Business The Company paid $0.6 million in cash in exchange for these patents and patent applications in the year ended December 31, 2017. The useful life of the patents was determined to be 12 years and 4 months and will be amortized through November 25, 2028. The Company recorded amortization expense of approximately $140,000 with net carrying amount of approximately $1,477,000 as of December 31, 2017. At December 31, 2017, a note payable of $480,000 is recorded on the consolidated Balance Sheet in connection with the final payment due by December 31, 2018. For fiscal years 2018 to 2022, approximately $135,000 will be recorded annually as amortization expense for the Neoptics assets. Costs incurred to develop software for the Company’s website are capitalized and amortized over the estimated useful life of the software and are included in intangible assets. Costs related to design or maintenance of website development is expensed as incurred. For the years ended December 31, 2017 and 2016, the Company capitalized $0 associated with website development. Amortization expense of $15,000 was recorded in each of the years ended December 31, 2017 and 2016.
Comprehensive Loss	Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the years ended December 31, 2017 and 2016.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when there is persuasive evidence that an arrangement exists with the customer, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue is recognized upon shipment and payments are either received in advance, or net 30 days. In the years ended December 31, 2017 and 2016 there were four and three customers, respectively, that represented 100% of total sales recognized for each year. As of December 31, 2017, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’s revenues are derived from foreign customers. The Company recognized revenues of $14,000 from foreign ophthalmic clinics during the years ended December 31, 2017 and 2016.
Clinical Trials	Clinical Trials In February 2015, the Company received approval from the FDA to commence enrollment of the second stage of its U.S. staged pivotal clinical trial of its Microlens involving the implantation of presbyopic patients. Enrollment for the second stage was completed in September 2015. The first staged-enrollment commenced during the first quarter of 2014, and during these trials, the Company incurred costs for patient recruiting, acquisition of clinical test equipment to be used in the trials, outside experts to read and interpret the results of the studies, third party costs to monitor the investigational sites and perform data collection activities and surgeon and patient fees in connection with the surgical procedures and follow-up visits. The Company’s policy with respect to the recognition of these costs is to record such costs as research and development expense in the consolidated statements of operations and comprehensive loss in the period in which the services are provided. The Company will evaluate the purchases of clinical test equipment, on a case by case basis, to determine if there exists an alternative use for the equipment following the clinical trials. In the event that the Company determines that there is no alternative use for the test equipment, that cost will be expensed as part of research and development expense.
Stock-Based Compensation	Stock-Based Compensation The compensation cost of stock-based awards granted to employees is measured at grant date, based on the estimated fair value of the award. The Company estimates the fair value of stock options using a Black-Scholes option pricing model. Additionally, the fair value of restricted stock units is determined using a Monte Carlo Simulation, or “MCS”, methodology, which considers the separate probabilities that of the price thresholds or market conditions will be achieved under the Restricted Stock Units Plan guidelines. Compensation expense for options granted to non-employees is determined as the fair value of consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Stock-based compensation costs are expensed on a straight-line basis over the service period. The fair value of awards granted to non-employees is remeasured each period until the related service is complete or there exists a significant disincentive not to perform the required services. Stock-based compensation costs are reflected in the accompanying statements of operations and comprehensive loss based upon the underlying employees’ roles within the Company.
Deferred Offering Costs	Deferred Offering Costs Generally, costs incurred such as legal, accounting and other professional fees including printing costs in the course of preparing for a capital raise are deferred on the balance sheet as deferred offering costs, which are eventually reclassified when the capital raise is concluded as a reduction of the proceeds of the capital raise as part of additional paid in capital. On December 5, 2016, the Company filed with the SEC a Form S-1 Registration Statement under the Securities Act of 1933 for the purpose of distributing to holders of the Company’s ordinary shares, non-transferable and non-tradeable subscription rights to purchase ordinary shares (“rights offering”). During the years ended December 31, 2017 and 2016, the Company incurred approximately $0.3 million and $0.2 million related to its rights offering, respectively, which was completed on March 8, 2017. Upon completion of the rights offering, the Company netted approximately $0.3 million in offering costs against the gross proceeds in shareholders’ equity as of December 31, 2017.
Income Taxes	Income Taxes As described in Note 1, the Parent completed a restructuring on October 21, 2013. As a result, some of the entities are no longer pass-through entities or were restructured as taxable entities. Provisions for federal, foreign, state, and local income taxes are calculated on pre-tax income based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Deferred income tax assets and liabilities are recorded for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is recorded to reduce net deferred income tax assets to amounts that are more likely than not to be realized.
Advertising Costs	Advertising Costs The Company incurs direct response advertising expense outside the United States in order to create awareness of the Company’s Microlens solution to presbyopia. The Company’s policy with respect to direct response advertising is to defer costs related to media and setup costs and amortize those costs to the consolidated statements of operations and comprehensive loss in the period in which the related revenue is recognized. Due to the early stages of market development and the uncertainty around the impact of advertising campaigns to-date, the Company expensed approximately $395,000, and $198,000 as part of sales and marketing expense in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2017 and 2016, respectively.
Risks and Uncertainties	Risks and Uncertainties The Company’s product requires the approval of the FDA and regulatory agencies in the countries where the Company operates or expects to establish operations in the future. There is no assurance that the Company’s
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes ASU 2015-17 became effective January 1, 2017 and did not have a material impact on our consolidated financial statements. In March 2016, the Financial Accounting Standards Board issued ASU 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting ASU 2016-09 became effective January 1, 2017 and did not have a material impact on our consolidated financial statements.
Future Accounting Pronouncements	Future Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-2 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In October 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting, In February 2018, the FASB issued Accounting Standards Update (“ASU”) No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Summary of Finished Goods Inventory	Finished goods inventory consists of the following (in thousands): December 31, 2017 2016 Lenses $ 55 $ 175 Accessories 72 127 Inventory $ 127 $ 302

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): December 31, 2017 2016 Office equipment and computers $ 79 $ 78 Leasehold improvements 214 168 Production equipment and facilities 802 788 Software 62 62 Furniture and vehicles 237 227 1,394 1,323 Less: accumulated depreciation (917 ) (596 ) Property and equipment, net $ 477 $ 727

Note Payable (Tables)

Note Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Summary of Note Payable	Note payable is summarized as follows (in thousands): December 31, 2017 2016 Noninterest bearing note payable to Neoptics A.G. $ 518 $ 981 Less present value discount (38 ) (122 ) Note payable, net 480 859 Less current portion 480 490 Note payable, long term $ — $ 369

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Other Liabilities Current [Abstract]
Summary of Other Current Liabilities	Other current liabilities consist of the following as of the dates set forth below (in thousands): December 31, 2017 2016 Accrued payroll and severance related $ 352 392 Accrued professional fees 109 71 Accrued clinical expense 125 — Accrued deferred rent expense 236 52 Accrued other expense 46 67 Income tax payable 283 52 $ 1,151 $ 634

Loss per Share (Tables)

Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted net loss per share were calculated as follows (in thousands, except share and per share data): December 31, 2017 2016 Net Loss $ (16,998 ) $ (15,757 ) Net income allocated to participating securities — — Net loss allocated to common shareholders $ (16,998 ) $ (15,757 ) Weighted average shares outstanding - basic and diluted 16,298,505 13,337,560 Basic and diluted net loss per share $ (1.04 ) $ (1.18 )

Equity Based Awards (Tables)

Equity Based Awards (Tables)	12 Months Ended
	Dec. 31, 2017
Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss	The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2017 and 2016. Year Ended December 31, 2017 2016 Research and development $ 251 $ 259 General and administrative 951 1,549 Sales and marketing (34 ) 363 $ 1,168 $ 2,171
Schedule of Option Activity	The following table sets forth the Company’s option activity for the year ended December 31, 2017: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance, January 1, 2017 1,050,000 $ 9.77 — Granted — $ — — Exercised — $ — — Forfeited/cancelled/expired (200,900 ) $ 9.74 — Balance, December 31, 2017 849,100 $ 9.77 — Vested, December 31, 2017 590,800 $ 9.80 — Not Vested, December 31, 2017 258,300 $ 9.72 — Exercisable, December 31, 2017 590,800 $ 9.80 —
Schedule of Restricted Shares Activity	The following table sets forth the Company’s restricted share activity for the year ended December 31, 2017: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2016 81,682 $ 3.50 Granted 89,166 $ 3.58 Vested (36,481 ) $ 2.96 Forfeited/cancelled — — Unvested, December 31, 2017 134,367 $ 3.78
Schedule of RSU Activity	The following table sets forth the Company’s RSU activity for the year ended December 31, 2017: Unvested Number of Weighted Average Fair Shares Value per Share Balance, December 31, 2016 719,000 $ 3.10 Granted 97,500 $ 1.92 Vested — $ — Forfeited/cancelled (77,500 ) $ 2.90 Unvested, December 31, 2017 739,000 $ 2.09
Non-employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	During the years ended December 31, 2017 and 2016, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Year Ended December 31, 2017 2016 Stock price per share $1.31 - $2.83 $2.50 - $3.49 Expected term 7.5 - 8.3 Yrs. 8.2 - 9.3 Yrs. Volatility 69.3% - 85.8% 66.1% - 92.6% Dividends — — Risk-free rate 2.2% - 2.4% 1.4% - 2.5%

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Schedule of Amounts Due to Related Parties	The following table sets forth the amounts due to related parties reflected in the accompanying consolidated balance sheets (in thousands): Year Ended December 31, 2017 2016 Payable to related parties-current: Management services provided by related parties $ 35 $ 18 Less current portion $ 23 $ 18 Management services provided by related parties, long term $ 12 $ —

Operating Segments and Geogra30

Operating Segments and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Schedule of Revenues Generated from External Customers and Long-lived Assets by Area	The following table sets forth the Company’s revenues generated from external customers located in foreign countries and long-lived assets by area (in thousands): Year Ended December 31, Revenues 2017 2016 Australia $ 5 $ — New Zealand 1 — Canada — 1 Ireland — 14 Italy 3 — The Netherlands — (1 ) Germany 5 — Total $ 14 $ 14 Year Ended December 31, Long-lived Assets 2017 2016 U.S. 453 697 Foreign 24 30 Total $ 477 $ 727

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Annual Base Rental Cost Over the Term of the Leases	The following table shows the annual base rental cost over the term of the leases (in thousands). Years Ended December 31, Obligations Under Facility Leases 2018 $ 580 2019 569 2020 494 2021 283 2022 120 Thereafter — Total $ 2,046

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	The provision for income taxes consists of the following (in thousands): Year Ended December 31, 2017 2016 Current provision: Federal $ — $ — State 2 4 Foreign 243 72 Total current $ 245 $ 76 Deferred provision Federal (3,335 ) (255 ) State — — Foreign 1,065 (1,228 ) Total deferred (2,270 ) (1,483 ) Valuation allowance 2,270 1,483 Total deferred — — Total income tax provision $ 245 $ 76
Schedule of Reconciliation of Federal Statutory Rate to Effective Rate	A reconciliation of the federal statutory rate to the effective rate is as follows: Year Ended December 31, 2017 2016 Expected income tax benefit at federal statutory rate 35 % 35 % State tax provision, net of federal benefit (0 %) 0 % Foreign rate differential (15 %) (25 %) Nondeductible expenses (0 %) 0 % Foreign Tax (1 %) 0 % Change in valuation allowance (4 %) (10 %) Effect of Change in Tax Rate (9 %) 0 % Other (7 %) 0 % Income tax provision (1.4 %) (0.0 %)
Components of Deferred Tax Assets	The components of the Company’s deferred tax assets are summarized as follows (in thousands): Year Ended 2017 2016 Deferred tax assets: Net operating loss carryforwards $ 5,019 $ 4,444 Accrued expenses 31 195 Stock based compensation 0 (11 ) Deferred tax assets 5,050 4,628 Valuation allowance (5,033 ) (4,559 ) Net deferred tax assets 17 69 Deferred tax liabilities: Depreciation (17 ) (69 ) Total deferred tax liabilities (17 ) (69 ) Net deferred tax asset $ — $ —
Schedule of Reconciliation of Gross Unrecognized Tax Benefits	A reconciliation of gross unrecognized tax benefits is as follows: Year Ended December 31, 2017 2016 Balance at the beginning of the year — — Increases related to current year tax positions 199,000 — Balance at the end of the year $ 199,000 $ —

Basis of Presentation and Des33

Basis of Presentation and Description of the Business - Additional Information (Detail)	Aug. 03, 2015shares	Feb. 03, 2015USD ($)$ / sharesshares	Jan. 14, 2015USD ($)$ / sharesshares	Nov. 30, 2014USD ($)	Feb. 06, 2014USD ($)shares	Feb. 06, 2014EUR (€)€ / sharesshares	Dec. 31, 2017USD ($)Country$ / shares	Dec. 31, 2016USD ($)$ / shares
Basis Of Presentation [Line Items]
Date of incorporation							Feb. 6, 2014
Number of ordinary shares, value							$ 10,534,000
Ordinary shares, par value | $ / shares							$ 0.001	$ 0.001
Capitalization of amounts due to Parent per 2014 and 2015 Debt Conversions			$ 1,600,000	$ 23,500,000
Other issuance costs								$ 167,000
Number of country in which company is authorized to sell, market and perform procedure | Country							40
Accumulated deficit							$ 88,302,000	$ 71,304,000
IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares		4,166,667
Ordinary shares, price per share | $ / shares		$ 10
Gross proceeds from issuance of stock		$ 41,700,000
Underwriting discounts and commission costs		2,900,000
Other issuance costs		2,000,000
Net proceeds from issuance of stock		$ 36,800,000
2015 Capital Contribution [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares			9,166,667
Ordinary shares, par value | $ / shares			$ 0.01
Presbia Holdings [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares	9,666,667				40,000	40,000
Number of ordinary shares, value					$ 54,000	€ 40,000
Percentage of ownership interests						100.00%
Ordinary shares, par value | € / shares						€ 1
Presbia Holdings [Member] | IPO [Member]
Basis Of Presentation [Line Items]
Number of ordinary shares, shares issued | shares		500,000

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Additional Information (Detail) SFr in Millions	Aug. 02, 2016USD ($)Installment	Aug. 02, 2016CHF (SFr)Installment	Dec. 31, 2018	Dec. 31, 2017USD ($)SegmentCustomer	Dec. 31, 2016USD ($)Customer
Subsidiary Sale Of Stock [Line Items]
Number of operating segment | Segment				1
Short-term investment instruments				$ 0	$ 0
Expiration period of each lens				5 years
Net cash (used in) provided by investing activities				$ (198,000)	(285,000)
Net cash (used in) provided by financing activities				10,024,000	(682,000)
Payment to acquire patents and patent applications				125,000	145,000
Net carrying amount				1,479,000	1,494,000
Note payable				480,000	859,000
Software capitalized				0	0
Amortization expenses of capitalized software				$ 15,000	$ 15,000
Payments collection period				30 days	30 days
Number of customers | Customer				4	3
Revenues				$ 14,000	$ 14,000
Payment of offering costs					$ 167,000
Income tax rate				35.00%	35.00%
Rights Offering [Member]
Subsidiary Sale Of Stock [Line Items]
Rights offering costs				$ 300,000	$ 200,000
Payment of offering costs				300,000
Foreign [Member] | Laser Center Revenues [Member]
Subsidiary Sale Of Stock [Line Items]
Revenues				$ 14,000	$ 14,000
Sales [Member] | Customer Concentration [Member]
Subsidiary Sale Of Stock [Line Items]
Concentration risk, percentage				100.00%	100.00%
Patents [Member]
Subsidiary Sale Of Stock [Line Items]
Useful life				12 years 4 months
Intangible asset end of useful life				Nov. 25, 2028
Amortization expense				$ 140,000
Net carrying amount				1,477,000
Scenario, Plan [Member]
Subsidiary Sale Of Stock [Line Items]
Income tax rate			21.00%
Neoptics AG [Member]
Subsidiary Sale Of Stock [Line Items]
Aggregate purchase price of assets	$ 1,500,000	SFr 1.5
Number of equal installments | Installment	3	3
Payment to acquire patents and patent applications				600,000
Note payable				480,000
Estimated amortization expense, 2018				135,000
Estimated amortization expense, 2019				135,000
Estimated amortization expense, 2020				135,000
Estimated amortization expense, 2021				135,000
Estimated amortization expense, 2022				$ 135,000
Neoptics AG [Member] | First Installment [Member]
Subsidiary Sale Of Stock [Line Items]
Asset purchase price payable installment due date	Aug. 2, 2016	Aug. 2, 2016
Neoptics AG [Member] | Second Installment [Member]
Subsidiary Sale Of Stock [Line Items]
Asset purchase price payable installment due date	Dec. 31, 2017	Dec. 31, 2017
Neoptics AG [Member] | Third Installment [Member]
Subsidiary Sale Of Stock [Line Items]
Asset purchase price payable installment due date	Dec. 31, 2018	Dec. 31, 2018
Neoptics AG [Member] | Reclassification [Member]
Subsidiary Sale Of Stock [Line Items]
Net cash (used in) provided by investing activities					$ 516,000
Net cash (used in) provided by financing activities					$ (516,000)
Minimum [Member]
Subsidiary Sale Of Stock [Line Items]
Estimated life of property and equipment				3 years
Maximum [Member]
Subsidiary Sale Of Stock [Line Items]
Estimated life of property and equipment				10 years
Number of customers | Customer				1	1
General and Administrative Expense [Member]
Subsidiary Sale Of Stock [Line Items]
Aggregate foreign exchange gain (loss)				$ (59,000)	$ 1,000
Selling and Marketing Expense [Member]
Subsidiary Sale Of Stock [Line Items]
Advertising costs				$ 395,000	$ 198,000

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory write-downs reflecting excess quantities on hand recognized	$ 90	$ 278

Inventory - Summary of Finished

Inventory - Summary of Finished Goods Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory	$ 127	$ 302
Lenses [Member]
Inventory [Line Items]
Inventory	55	175
Accessories [Member]
Inventory [Line Items]
Inventory	$ 72	$ 127

Property and Equipment, net - S

Property and Equipment, net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,394	$ 1,323
Less: accumulated depreciation	(917)	(596)
Property and equipment, net	477	727
Office equipment and computers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	79	78
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	214	168
Production equipment and facilities [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	802	788
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	62	62
Furniture and vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 237	$ 227

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense		$ 322,000	$ 186,000
Furniture and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Unrecognized depreciation	$ 67,000
Engineering Tools, Molds and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Unrecognized depreciation	$ 52,000

Note Payable - Summary of Note

Note Payable - Summary of Note Payable (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Note payable, net	$ 480	$ 859
Less current portion	480	490
Note payable, long term		369
Note Payable To Neoptics AG [Member]
Debt Instrument [Line Items]
Noninterest bearing note payable to Neoptics A.G.	518	981
Less present value discount	$ (38)	$ (122)

Note Payable - Additional Infor

Note Payable - Additional Information (Detail) - Neoptics AG [Member] SFr in Millions	Aug. 02, 2016USD ($)Installment	Aug. 02, 2016CHF (SFr)Installment	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Aggregate purchase price of assets	$ 1,500,000	SFr 1.5
Number of equal installments | Installment	3	3
Payment description			No interest and payable in three equal installments on each of August 2, 2016, December 31, 2017 and December 31, 2018.
Loan discount rate			9.00%
Unamortized discount			$ 38,000
First Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Aug. 2, 2016	Aug. 2, 2016
Second Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Dec. 31, 2017	Dec. 31, 2017
Third Installment [Member]
Debt Instrument [Line Items]
Interest payable	$ 0
Asset purchase price payable installment due date	Dec. 31, 2018	Dec. 31, 2018

Other Current Liabilities - Sum

Other Current Liabilities - Summary of Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities Current [Abstract]
Accrued payroll and severance related	$ 352	$ 392
Accrued professional fees	109	71
Accrued clinical expense	125
Accrued deferred rent expense	236	52
Accrued other expense	46	67
Income tax payable	283	52
Total	$ 1,151	$ 634

Other Current Liabilities - Add

Other Current Liabilities - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)
Current Portion of Deferred Rent [Member]
Prior Period Adjustments Restatement [Line Items]
Prior period reclassification adjustment	$ 52,000

Loss per Share - Schedule of Ca

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Basic and diluted net loss per share
Net Loss	$ (16,998)	$ (15,757)
Net loss allocated to common shareholders	$ (16,998)	$ (15,757)
Weighted average shares outstanding - basic and diluted	16,298,505	13,337,560
Basic and diluted net loss per share	$ (1.04)	$ (1.18)

Loss per Share - Additional Inf

Loss per Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Antidilutive securities, not included in diluted net loss per calculation	1,037,964	1,082,916

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail)	Dec. 14, 2017USD ($)	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2017EUR (€)€ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2016€ / shares	Aug. 31, 2015shares	Jan. 14, 2015shares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014€ / shares
Class Of Stock [Line Items]
Ordinary shares, value authorized		$ 400,000	€ 40,000
Ordinary shares, shares authorized		350,000,000	350,000,000	350,000,000
Ordinary shares, par value | $ / shares		$ 0.001		$ 0.001
Deferred Ordinary shares | $		$ 54,000		$ 54,000				$ 54,000
Deferred ordinary shares, par value | (per share)		$ 1.35	€ 1	$ 1.35	€ 1			$ 1.35	€ 1
Deferred ordinary shares, shares authorized		39,994	39,994	39,994				40,000
Deferred ordinary shares, shares issued		39,994	39,994	39,994			40,000
Cash payment for ordinary shareholders upon winding up | $		$ 5,000,000
Preferred shares, shares authorized		50,000,000	50,000,000	50,000,000
Preferred shares, par value | $ / shares		$ 0.001		$ 0.001
Preferred shares, shares issued		0	0	0
Accessories [Member] | O C V Management L L C
Class Of Stock [Line Items]
Notice period for agreement termination	30 days
Annual fee payable | $	$ 250,000
Management services provided by related parties, non-current liability | $		$ 12,000
Richard Ressler
Class Of Stock [Line Items]
Deferred Ordinary Shares Transferred						39,994

Equity Based Awards - Additiona

Equity Based Awards - Additional Information (Detail)	Jan. 14, 2015shares	Dec. 31, 2017USD ($)Employeesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense | $				$ 1,168,000	$ 2,171,000
Non-employee consultants and medical advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted				0	0
Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Percentage of estimated forfeiture rate				3.00%
Options granted				0	0
Non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Percentage of estimated forfeiture rate				3.00%
Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period				1 year	3 years
Restricted shares granted				89,166	65,450
Weighted average grant date fair value | $ / shares				$ 3.58	$ 3.50
Restricted shares/RSUs outstanding		134,367	134,367	134,367	81,682
Restricted shares units vested				36,481
Unrecognized compensation expense, weighted average period of recognition				1 year 7 months 6 days	2 years 7 months 6 days
Unrecognized compensation expense related to restricted shares/RSUs | $		$ 200,000	$ 200,000	$ 200,000	$ 300,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Award expiration period				7 years
Percentage of estimated forfeiture rate				3.00%
Restricted shares granted				97,500
Authorized issuance percentage of each recipient’s total RSU award				20.00%
Consecutive trading days				20 days
Wait or service period				1 year
Allocated share-based compensation expense | $				$ 302,000	$ 467,000
Restricted shares/RSUs outstanding		739,000	739,000	739,000	719,000
Restricted shares units vested				0
Unrecognized compensation expense, weighted average period of recognition				2 years
Unrecognized compensation expense related to restricted shares/RSUs | $		$ 7,300,000	$ 7,300,000	$ 7,300,000
Restricted Stock Units [Member] | New Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted				60,000
Restricted Stock Units [Member] | Existing Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted				37,500
Employee and non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense related to options | $		$ 500,000	500,000	$ 500,000	$ 3,400,000
Unrecognized compensation expense, weighted average period of recognition				1 year 6 months	2 years
Reorganization [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Number of employees terminated | Employees		15
Reduction in share based compensation | $		$ 970,000	$ 970,000
Threshold Price Period 1 [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold | $ / shares				$ 10
Threshold Price Period 2 [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold | $ / shares				15
Threshold Price Period 3 [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold | $ / shares				20
Threshold Price Period 4 [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold | $ / shares				25
Threshold Price Period 5 [Member] | Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold | $ / shares				$ 30
Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period	5 years
Ordinary shares authorized for issuance	2,200,000
Ordinary shares available for future grants and awards		435,141	435,141	435,141
Award expiration period	10 years
Award expiration date				Jan. 14, 2025
Presbia Incentive Plan [Member] | Over five year period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual	20.00%

Equity Based Awards - Share-Bas

Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 1,168	$ 2,171
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	251	259
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	951	1,549
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ (34)	$ 363

Equity Based Awards - Schedule

Equity Based Awards - Schedule of Option Activity (Detail)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Presbia PLC Shares, Beginning Balance | shares	1,050,000
Number of Presbia PLC Shares, Forfeited/cancelled/expired | shares	(200,900)
Number of Presbia PLC Shares, Ending Balance | shares	849,100
Number of Presbia PLC Shares, Vested | shares	590,800
Number of Presbia PLC Shares, Not Vested | shares	258,300
Number of Presbia PLC Shares, Exercisable | shares	590,800
Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 9.77
Weighted Average Exercise Price Per Share, Forfeited/cancelled/expired | $ / shares	9.74
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	9.77
Weighted Average Exercise Price Per Share, Vested | $ / shares	9.80
Weighted Average Exercise Price Per Share, Not Vested | $ / shares	9.72
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 9.80

Equity Based Awards - Schedul49

Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - Non-employee options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Volatility minimum	69.30%	66.10%
Volatility maximum	85.80%	92.60%
Risk-free rate minimum	2.20%	1.40%
Risk-free rate maximum	2.40%	1.50%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 1.31	$ 2.50
Expected term	7 years 6 months	8 years 2 months 12 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 2.83	$ 3.49
Expected term	8 years 3 months 18 days	9 years 3 months 18 days

Equity Based Awards - Schedul50

Equity Based Awards - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member] - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance	81,682
Unvested Number of Shares, Granted	89,166	65,450
Unvested Number of Shares, Vested	(36,481)
Unvested Number of Shares, Ending Balance	134,367	81,682
Weighted Average Fair Value per Share, Beginning Balance	$ 3.50
Weighted Average Fair Value per Share, Granted	3.58
Weighted Average Fair Value per Share, Vested	2.96
Weighted Average Fair Value per Share, Ending Balance	$ 3.78	$ 3.50

Equity Based Awards - Schedul51

Equity Based Awards - Schedule of RSU Activity (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance	719,000
Unvested Number of Shares, Granted	97,500
Unvested Number of Shares, Vested	0
Unvested Number of Shares, Forfeited/cancelled	(77,500)
Unvested Number of Shares, Ending Balance	739,000
Weighted Average Fair Value per Share, Beginning Balance | $ / shares	$ 3.10
Weighted Average Fair Value per Share, Granted | $ / shares	1.92
Weighted Average Fair Value per Share, Forfeited/cancelled | $ / shares	2.90
Weighted Average Fair Value per Share, Ending Balance | $ / shares	$ 2.09

Related Party Transactions - Sc

Related Party Transactions - Schedule of Amounts Due to Related Parties (Detail) - Management services [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Payable to related parties-current:
Management services provided by related parties	$ 35	$ 18
Less current portion	23	$ 18
Management services provided by related parties, long term	$ 12

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Dec. 14, 2017	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due to related parties		$ 23,000	$ 18,000
Orchard Capital Corporation [Member]
Related Party Transaction [Line Items]
General and administrative expense		14,000	14,000
Orchard Capital Corporation [Member] | Management and Accounting Services [Member]
Related Party Transaction [Line Items]
Due to related parties		3,000	4,000
C I M Group L P
Related Party Transaction [Line Items]
Due to related parties		19,000	14,000
Charges incurred		$ 37,000	$ 73,000
O C V Management L L C | Accessories [Member]
Related Party Transaction [Line Items]
Notice period for agreement termination	30 days
Annual fee payable	$ 250,000
Related party transaction, terms		On December 14, 2017, the Company concluded a services agreement with OCV Management, LLC, a related party co-founded by Mr. Ressler and Mark Yung, for the purpose of providing management services for the Company for the period commencing December 14, 2017 until terminated upon thirty (30) days’ prior written notice by either of the parties. OCV Management, LLC will receive an annual fee of $250,000, payable annually in arrears. The obligation will be settled in the form of ordinary shares issued by the Company in a private offering. For 2018, the number of shares to be issued will be determined by dividing $250,000 by the closing price on January 2, 2018 and the shares will be issued on January 2, 2019. The Company recorded a non-current liability of $12,000 as of December 31, 2017 in relation to services provided in 2017 (see Note 15).
Management services provided by related parties, non-current liability		$ 12,000

Operating Segments and Geogra54

Operating Segments and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2017SegmentCustomer	Dec. 31, 2016Customer
Segment Reporting Revenue Reconciling Item [Line Items]
Number of reportable segments | Segment	1
Number of customers	4	3
Supplier agreement term	5 years
Sales [Member] | Customer Concentration [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk percentage	100.00%	100.00%
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Concentration risk percentage	100.00%
Maximum [Member]
Segment Reporting Revenue Reconciling Item [Line Items]
Number of customers	1	1

Operating Segments and Geogra55

Operating Segments and Geographic Information - Schedule of Revenues Generated from External Customers and Long-lived Assets by Area (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 14	$ 14
Long Lived Assets	477	727
Australia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	5
New Zealand [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	1
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		1
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		14
Italy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	3
The Netherlands [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		(1)
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	5
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	453	697
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long Lived Assets	$ 24	$ 30

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Facility Leases [Member] - USD ($)	Aug. 01, 2016	Jun. 01, 2016	Jan. 02, 2016	Dec. 01, 2013	May 31, 2012	Dec. 31, 2017	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Rent expense						$ 867,000	$ 388,000
California [Member]
Commitments And Contingencies [Line Items]
Non-cancelable lease term					5 years
Lease expiration period	Sep. 30, 2020				May 31, 2017
Non-cancelable lease extended term		5 years
Extended lease expiration date		May 31, 2022
Lease period	4 years
Lease commencement date	Aug. 1, 2016
Ireland [Member]
Commitments And Contingencies [Line Items]
Lease period				1 year
Lease renewal term				1 month
Lease commencement date				Dec. 1, 2013
The Netherlands [Member]
Commitments And Contingencies [Line Items]
Lease period			30 months
Lease commencement date			Jan. 1, 2016
Lease termination period			2018-02

Commitment and Contingencies -

Commitment and Contingencies - Annual Base Rental Cost Over the Term of the Leases (Detail) - Facility Leases [Member] $ in Thousands	Dec. 31, 2017USD ($)
Operating Leased Assets [Line Items]
2,018	$ 580
2,019	569
2,020	494
2,021	283
2,022	120
Total	$ 2,046

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Current provision:
Federal	$ 0	$ 0
State	2	4
Foreign	243	72
Total current	245	76
Deferred provision
Federal	(3,335)	(255)
State	0	0
Foreign	1,065	(1,228)
Total deferred	(2,270)	(1,483)
Valuation allowance	2,270	1,483
Total deferred	0	0
Total income tax provision	$ 245	$ 76

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Federal Statutory Rate to Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Expected income tax benefit at federal statutory rate	35.00%	35.00%
State tax provision, net of federal benefit	0.00%	0.00%
Foreign rate differential	(15.00%)	(25.00%)
Nondeductible expenses	0.00%	0.00%
Foreign Tax	(1.00%)	0.00%
Change in valuation allowance	(4.00%)	(10.00%)
Effect of Change in Tax Rate	(9.00%)	0.00%
Other	(7.00%)	0.00%
Income tax provision	(1.40%)	0.00%

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 5,019	$ 4,444
Accrued expenses	31	195
Stock based compensation	0	(11)
Deferred tax assets	5,050	4,628
Valuation allowance	(5,033)	(4,559)
Net deferred tax assets	17	69
Deferred tax liabilities:
Depreciation	(17)	(69)
Total deferred tax liabilities	$ (17)	$ (69)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Operating loss carryforwards		$ 11,100,000	$ 2,000,000
Operating loss carryforwards expiration year		2,033
Operating Loss Carryforwards, Limitations on Use		NOL carryforwards may be limited in the event a cumulative change in ownership of 50% of certain shareholders occurs within a three year period
Liability for unrecognized tax benefits relating to foreign income tax matter		$ 199,000
Accrued interest and penalties		$ 39,000	$ 0
Federal tax at statutory rate		35.00%	35.00%
Decrease in net deferred tax assets		$ 1,567,000
Scenario, Plan [Member]
Income Tax [Line Items]
Federal tax at statutory rate	21.00%
Ireland [Member]
Income Tax [Line Items]
Operating loss carryforwards		$ 21,500,000	$ 21,200,000
Operating Loss Carryforwards, Limitations on Use		Under Irish rules, only such losses that occur within a three year period prior to commencing trading can be utilized to offset future trading taxable income.

Income Taxes - Schedule of Re62

Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 0	$ 0
Increases related to current year tax positions	199,000	0
Balance at the end of the year	$ 199,000	$ 0

Fourth Quarter 2017 Adjustmen63

Fourth Quarter 2017 Adjustments - Additional Information (Detail) - Reorganization [Member]	1 Months Ended	3 Months Ended
	Dec. 31, 2017USD ($)ft²EmployeesFacility	Dec. 31, 2017USD ($)
Restructuring Cost And Reserve [Line Items]
Number of employees reduced | Employees	15
Percentage of employees reduced	38.50%
Reduction in operating expense	$ 1,078,000
Increase in tax provision expense	238,000
Compensation related adjustments	465,000	$ 465,000
Severance costs	332,000
Reversal of accrued incentive compensation costs	797,000	$ 797,000
Facilities related adjustments	357,000
Period to exercise vested options following termination		90 days
Terms and conditions for terminated employees awards vesting description		On the date of reorganization, the Company extended the terms and conditions for all equity grants for all terminated employees providing at least a one-year extension past the termination date for all vested stock options (Type I modification as prescribed by ASC 718), and, in certain cases, the acceleration of unvested options or restricted share awards (Type III modification as prescribed by ASC 718). For those terminated employees with RSU grants based on a market condition, the Company granted a one-year extension to vest according to the same market conditions as defined in the original grants. Generally, when a modification of an award occurs, the prior periods’ expense recognition associated with all unvested awards is reversed in the period of the modification on the basis that the old award is being exchanged for a new award.
Reduction of stock-based compensation expense		$ 1,350,000
Increase in fair value as stock-based compensation expense		380,000
Reduction in share based compensation	970,000	970,000
Accrued Expense [Member]
Restructuring Cost And Reserve [Line Items]
Write-down of leasehold expenses	8,000
Furniture and Fixtures [Member]
Restructuring Cost And Reserve [Line Items]
Write-down of leasehold expenses	89,000
Engineering Tools, Molds and Fixtures [Member]
Restructuring Cost And Reserve [Line Items]
Write-down of leasehold expenses	$ 52,000
Irvine [Member]
Restructuring Cost And Reserve [Line Items]
Number of facilities vacated | Facility	1
Vacated facility lease area | ft²	8,500
Vacated facility remaining lease term	33 months
Vacated facility lease expiration period	Sep. 30, 2020
Fair value of remaining lease obligation	$ 222,000	222,000
Irish Tax Authorities [Member]
Restructuring Cost And Reserve [Line Items]
Tax reserve for unpaid withholding taxes	238,000	238,000
Withholding of income taxes to be paid	238,000	238,000
Estimated remittance amount intends to recover from directors	$ 70,000	$ 70,000

Subsequent Events - Additional

Subsequent Events - Additional information (Detail) - Management services [Member] - O C V Management L L C - Service Agreement [Member] - USD ($)	Jan. 02, 2018	Dec. 14, 2017
Subsequent Events [Line Items]
Annual fee payable		$ 250,000
Subsequent Events [Member]
Subsequent Events [Line Items]
Closing price of ordinary shares	$ 3.29
Number of ordinary shares required to settle in January 2019	75,988